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Abstract
Introduction: We aimed to design a real-time reverse-transcriptase-PCR (rRT-PCR), high-resolution melting (HRM) assay to
detect the H275Y mutation that confers oseltamivir resistance in influenza A/H1N1 2009 viruses.
Findings: A novel strategy of amplifying a single base pair, the relevant SNP at position 823 of the neuraminidase gene, was
chosen to maintain specificity of the assay. Wildtype and mutant virus were differentiated when using known reference
samples of cell-cultured virus. However, when dilutions of these reference samples were assayed, amplification of non-
specific primer-dimer was evident and affected the overall melting temperature (Tm) of the amplified products. Due to
primer-dimer appearance at .30 cycles we found that if the cycle threshold (CT) for a dilution was .30, the HRM assay did
not consistently discriminate mutant from wildtype. Where the CT was ,30 we noted an inverse relationship between CT
and Tm and fitted quadratic curves allowed the discrimination of wildtype, mutant and 30:70 mutant:wildtype virus
mixtures. We compared the CT values for a TaqMan H1N1 09 detection assay with those for the HRM assay using 59 clinical
samples and demonstrated that samples with a TaqMan detection assay CT.32.98 would have an H275Y assay CT.30.
Analysis of the TaqMan CT values for 609 consecutive clinical samples predicted that 207 (34%) of the samples would result
in an HRM assay CT.30 and therefore not be amenable to the HRM assay.
Conclusions: The use of single base pair PCR and HRM can be useful for specifically interrogating SNPs. When applied to
H1N1 09, the constraints this placed on primer design resulted in amplification of primer-dimer products. The impact
primer-dimer had on HRM curves was adjusted for by plotting Tm against CT. Although less sensitive than TaqMan assays,
the HRM assay can rapidly, and at low cost, screen samples with moderate viral concentrations.
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Introduction
During the influenza A/H1N1 2009 pandemic the widespread
use of oseltamivir has been a key component of efforts to treat
individual patients and provide prophylaxis for those at risk. Of
concern there are now not only isolated reports of detection of
oseltamivir resistant virus [1,2,3] but also evidence of emergence
of oseltamivir-resistance during prophylaxis [4] and community
clusters of cases [5]. To date, documented oseltamivir resistant
influenza A/H1N1 2009 viruses carry a single nucleotide
polymorphism (SNP) at position 823 (cytosine to thymine) of the
neuraminidase gene which results in a histidine to tyrosine
substitution at position 275 [6]. Detection of resistant virus is
usually performed by phenotypic assays such as neuraminidase
inhibition assays, or by sequencing of viral nucleic acid [7]. These
assays are time consuming and often restricted to reference and
research laboratories. In addition, they can lack sensitivity when
there is insufficient viral concentration in clinical samples, or in the
case of the phenotypic assay require a cultured isolate.
High-resolution melting analysis is an emerging technology that
is based on monitoring the separation of double stranded DNA as
the temperature is increased in the presence of DNA intercalating
dyes. The advantages of HRM are that it is a single-step closed
tube process incorporating the steps of reverse transcriptase and
post-amplification analysis, and that it requires no reagents beyond
real-time PCR master-mix and unlabelled oligonucleotide primers,
so it is inherently simple and cost effective. HRM analysis of the
neuraminidase gene has been used for typing of influenza [8] but
not for the determination of oseltamivir resistance monitoring.
The challenges for detecting the H275Y mutation are that the
assay needs to be specific for the C to T SNP at position 823 and
needs to take into account the potential impact upon melting
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in clinical samples. This report describes a SYBR green based real-
time reverse transcription PCR (rRT-PCR) followed by HRM
analysis to detect the H275Y mutation and the methodologies to
address the challenges observed.
Methods
Ethics statement
The conduct of this study was approved by the Human
Research Ethics Committee (HREC) of the Northern Territory
Department of Health & Families and Menzies School of Health
Research (HREC reference number 09/79). The HREC deemed
that individual consent was not required from patients as there was
no collection of identifying information in association with the
samples used.
Reference samples
Five oseltamivir sensitive influenza A/H1N1 2009 viral samples
(A/Victoria/2048/2009, A/Victoria/2116/2009, A/Denmark/
524/2009, A/Perth/184/2009, A/Brisbane/108/2009) and five
samples that contained oseltamivir resistant (H275Y) virus (A/
Osaka/180/2009, A/Perth/268/2009, A/Victoria/3132/2009,
A/Denmark/528/2009, A/Perth/262/2009) were used as refer-
ence samples. Pyrosequencing and neuraminidase inhibition
assays were used to detect the presence and relative mix of
H275Y mutant strains [9]. To determine the specificity of the
HRM assay for influenza A/H1N1 2009 we used five influenza A/
H1N1 seasonal (non 2009) and three influenza A/H3N2 as
negative control strains. RNA was extracted by the Roche
MagNaPure LC protocol (Roche Diagnostics Australia, Castle
Hill, NSW, Australia). The HRM assay was tested against 10-fold
serial dilutions of extracted RNA from wildtype and mutant
influenza A/H1N1 2009 samples and mixtures of mutant:wildtype
virus at 10:90 and 30:70 ratios. Starting concentrations of RNA
were quantified by using absorption of light at 260 and 280 nm
(A260/280) with a Biowave DNA spectrophotometer (Biochrom
WPA, Blackburn, Victoria, Australia).
Clinical specimens
We validated the HRM assay on 69 influenza positive clinical
samples from the Royal Darwin Hospital. Samples were obtained
from patients with an influenza-like illness between June 1 to
August 30 2009 by nose and throat swabs. Swabs were placed in
viral transport medium and RNA extracted by the Roche
MagNaPure LC protocol. All samples were tested with TaqMan
assays targeting the influenza A matrix gene and, if positive,
subsequently targeting the haemaglutinin gene of influenza A/
H1N1 2009 [10]. Of the 69 samples, 59 were influenza A/H1N1
2009, 3 were influenza A/H1N1 seasonal, and 7 were influenza
A/H3N2.
HRM assay design and protocol
We designed primers specific for influenza A/H1N1 2009 based
on sequences of the NA gene downloaded from the National
Center of Biotechnology Information from September 2009. A
novel strategy of only amplifying a single base pair, the SNP at
position 823, was chosen to maintain the specificity of the HRM
assay. We were concerned that if the amplified region was
extended, other sequence variations in the region of position 823
would non-specifically alter the melting temperature and melting
curve. The primers were: H275Y F: 59 GTCAAATCAGTC-
GAAATGAATGCCCCTAATTAT and H275Y R: 59 GGA-
TAACAGGAGCATTCCTCATAGT. The resulting product was
predicted to have a lower melting temperature (Tm) in the
presence of a thymine (mutant) compared to a cytosine (wildtype)
at position 823. These primers were predicted to form cross-
dimers with a free energy (DG) of 210.09 (http://www.
premierbiosoft.com/netprimer/index.html) and shortening or
lengthening the primers did not appreciably reduce the likelihood
of cross-dimer formation. We decided that the need for specificity
of the HRM assay, and thus constraints upon primer positioning,
would likely outweigh problems caused by potential primer-dimer
formation.
We used a step-down PCR amplification method to improve
specificity. Each reaction contained 5 mL QuantiFast SYBR
Green RT-PCR Kit master mix (Qiagen, Doncaster, Victoria,
Australia), 0.5 mM of each primer, 1 mL RT-mix and 1 mL RNA
template in a final volume of 10 mL. The real-time PCR
thermocycling parameters were: 50uC for 10 min, 95uC for
5 min; 4 sets of 2 cycles each of 95uC for 2 s and decreasing
annealing temperatures from 68uCt o6 2 uCi n2 uC decrements for
6 s; 27 cycles of 95uC for 2 s, 60uC for 6 s; and 50uC for 20 s;
followed by HRM ramping from 69uCt o7 9 uC with fluorescence
data acquisition at 0.2uC increments. The total reaction time was
62 minutes. Reactions were performed on a Rotor-Gene 6000
(Corbett Life Science, Concorde, NSW, Australia) instrument.
These can no longer be purchased, but the QIAGEN Rotor-Gene
Q devices are essentially identical.
Statistical analysis
Raw data were exported from the Corbett Rotor-Gene 6000
software v.1.7 into Microsoft Excel 2007 (Microsoft, Redmond,
Washington, USA) and Stata 10.1 (StataCorp LP, Texas, USA) for
graphical and statistical analysis.
Results
Assay design and proof of principle using dilutions of
reference samples
We initially tested the assay using dilutions of reference samples
with wildtype (A/Victoria/2048/2009) and mutant (A/Osaka/
180/2009) viruses. The cycle thresholds (CT) for the serial 10-fold
dilutions were as predicted for such a series (Fig. 1A). It was also
evident that non-specific primer-dimer amplification occurred as
demonstrated by the presence of amplification products after cycle
30 in no-template controls and non influenza A/H1N1 2009
controls. Although the undiluted samples could be clearly
differentiated based on the Tm and normalized fluorescence
curves, there was overlap in the normalized fluorescence curves
when comparing a 10
24 dilution of wildtype and the undiluted
mutant containing sample (Fig. 1B). The presence of primer-
dimer explains the downward Tm shift with reducing concentra-
tions of template RNA (Fig. 1B). The primer-dimer product has a
lower Tm compared to the desired amplification product. As the
concentration of template RNA decreases, the proportional
representation of end product due to primer-dimer increases,
and therefore the overall Tm of the end product is decreased.
Addition of Q solution (Qiagen Australia, Doncaster, Victoria,
Australia) eliminated the detectable amplification of primer-dimers
but significantly reduced the sensitivity of the amplification and
resulted in less reproducible determination of the Tm values (data
not shown). We concluded that the assay is more robust in the
absence of Q solution and that the constraints upon primer
placement made primer-dimer formation inevitable.
We therefore made allowance for the appearance of primer-
dimer at .30 cycles by two means. We deemed that if the CT for a
sample was .30, the HRM assay was no longer able to consistently
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detection of the assay was a 10
24 dilution of a starting RNA
concentration of virus of 6.1 ng/mL that is the equivalent of 10
5
gene copies/mL( Fig. 1A). We also noted the consistent inverse
relationship between Tm and CT; samples with lower concentra-
tions of RNA and a higher CT also had a lower Tm (Fig. 1A). We
adjusted for this by plotting Tm against CT. The fitted quadratic
curves with 95% confidence intervals for wildtype and mutant
containing samples, and also 30:70 mutant virus mixtures, could
now easily be discriminated (Fig. 2). The quadratic curve for the
Figure 1. Relationship between cycle threshold and melting temperature. The relationship between cycle threshold (CT) and melting
temperature (Tm) demonstrated by ten-fold serial dilutions of wildtype (H) (A/Victoria/2048/2009) and mutant (Y) (A/Osaka/180/2009) virus samples.
A. The CT increases as the RNA template concentration decreases. The no template control (NTC) demonstrates late amplification after cycle 30,
indicating the presence of primer-dimer. B. The Tm on the high-resolution melting normalized fluorescence graph decreases as the RNA template
concentration decreases. The NTC melts at the lowest temperature. As the amplified product contains increasing proportions of the primer-dimer, the
overall Tm is pulled towards that of the primer-dimer.
doi:10.1371/journal.pone.0021446.g001
HRM Detection of H275Y in Influenza A/H1N1 2009
PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e2144630:70 mix serves as a useful cut-off; points lying above this line will
contain a minority of mutant virus, and points below this line will
contain a significant proportion of mutant virus.
Validation with additional defined reference samples
Using these methods, eight blinded reference samples were
correctly called; three were wildtype and five mutant containing
samples. This included one sample that plotted above the mutant
curve but below the 30:70 mixture curve. Pyrosequencing of this
sample revealed a 34:66 mutant:wildtype mixture. The raw data of
CT and Tm of these reference samples is provided (Results S1).
Validation with clinical sample material
We excluded clinical samples from the Royal Darwin Hospital
that had an influenza A/H1N1 2009 Taqman detection assay [10]
CT.35 as we considered that there would unlikely be enough
RNA present in these samples for the H275Y assay. Subsequently
we randomly selected 59 clinical samples that had been
determined to have an influenza A/H1N1 2009 TaqMan
detection assay CT ranging from 22.52 to 32.95. The correspond-
ing range of H275Y assay CT was 19.8 to 30.77. Fifty-six clinical
samples were predicted to be wildtype (Fig. 2), of which 28 were
pyrosequenced and confirmed as such. Three samples (with
TaqMan detection assay CT of 29.81, 31.01 and 31.15) had
H275Y assay CT.30 for which we considered the HRM assay
would not be robust due to the poor amplification. The Pearson
correlation coefficient for the CT of the two assays was 0.92
(P,0.0001). Linear regression analysis predicted that samples with
a TaqMan detection assay CT.32.98 would have an H275Y assay
CT.30. We reviewed the TaqMan assay CT for 609 consecutive
positive clinical samples at the Royal Darwin Hospital and found
that the HRM assay would be predicted to have a CT.30 in 34%
(207 of 609) of clinical samples. All ten non influenza A/H1N1
2009 controls had a CT of .30 cycles.
Discussion
We have developed and evaluated a rRT-PCR HRM diagnostic
assay to detect oseltamivir resistance due to the H275Y mutation
in H1N1 2009 influenza viruses. Other RT-PCR assays to detect
H275Y in influenza make use of various techniques including RT-
PCR followed by restriction fragment length polymorphism [11],
discrimination based on amplification curves with fluorescent
TaqMan probes [12,13,14,15,16,17,18], a SYBR-green based
rRT-PCR [19], rolling circle amplification [20] and a mismatch
amplification mutation assay [21]. Advantages of the currently
described HRM assay are its single-step, closed tube nature with
post-amplification SNP interrogation, and the low cost of reagents.
It is also rapid, with a total run time of 62 minutes. However, the
key limitation to this HRM assay is that clinical samples with a low
amount of viral RNA template cannot be reliably interrogated.
We have demonstrated two novel methodological approaches.
First, we used PCR to amplify a single base pair with subsequent
HRM analysis to ensure specificity of the HRM curves. Second,
due to the constraints this placed on primer design, non-specific
primer-dimer formation occurred and we successfully adjusted for
the impact this had on the overall Tm of the reaction by plotting
Tm against CT. Wildtype and mutant containing samples were
therefore clearly discriminated up to a CT of 30. The curve
generated for 30:70 mixed samples can be used as a cut-off to
separate samples containing a significant proportion of resistant
mutant virus; or alternatively, those samples with a Tm versus CT
value falling outside the confidence limits of the sensitive control
curve could be targeted for further evaluation.
Figure 2. Plot of the melting temperature (Tm) against the cycle threshold (CT). The blue, red, and green lines are the quadratic fitted lines
with 95% confidence intervals for dilutions (blue, red and green circles) of the controls of wildtype (H@275) (A/Victoria/2048/2009), mutant (Y@275)
(A/Osaka/180/2009), and 30:70 mix of mutant:wildtype respectively. The 10:90 mutant:wildtype consistently plotted below the wildtype fitted curve,
but at the lower border of the 95% confidence interval. All 56 clinical samples that had a CT#30 correlated with the wildtype virus (28 confirmed by
pyrosequencing). Blinded WHO samples (four wildtype and four mutant containing) and dilutions of mutant virus (A/Denmark/528/2009 and A/Perth/
262/2009) fit within the expected curves. One blinded sample (A/Perth/268/2009) plotted just below the 30:70 curve and pyrosequencing
determined this to be a 34:66 mix of mutant:wildtype. Raw data is provided in Results S1.
doi:10.1371/journal.pone.0021446.g002
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with different operators (data not shown). Our experience and
understanding is that the Rotor-Gene 6000 devices are extremely
accurate with regards to relative temperature changes. However,
the absolute temperature calibration may differ by up to 0.5uC
between different machines. Therefore, we recommend initial
calibration using samples of known mixtures of mutant and
wildtype samples.
The key limitation of this assay is that clinical samples with a
low amount of viral RNA template cannot be reliably interrogat-
ed. However, similar problems can exist for pyrosequencing and
some rRT-PCR assays where up to 20% of clinical samples
provided indeterminate results due to low viral load [17,19]. Also,
neuraminidase inhibition assays require the virus to be isolated in
tissue culture or eggs before testing, something that is very
problematic when samples have CT values .30. Other molecular
diagnostic assays that make use of labeled probes appear to be
more sensitive with detection limits ranging from 2–500 gene
copies/ml [13,15,18]. However, these assays are associated with
the additional expense of labeled probes, and assays using
TaqMan probes require two reactions per sample. A mismatch
amplification mutation PCR assay that does not require probes
has been described but also involves two reactions per sample as
well as an additional gel electrophoresis step following the PCR
reaction [21].
Given the simplicity (single reaction, single-step, closed-tube),
low cost (single pair of unlabeled oligonucleotide primers) and
rapidity of this HRM assay, we foresee a number of possible
applications. It could be used to screen a large number of clinical
samples that are known to contain sufficient amounts of virus.
Similarly, culture stocks of virus where there is a large
concentration of virus could be rapidly screened. Immunocom-
promised patients with persistent H1N1 09 infections and at risk of
development of oseltamivir resistance have been reported to have
low CT values [22] and this HRM assay may be useful in detecting
the H275Y mutation in virus from such patients. If there is an
urgent clinical need to determine if resistance is present and the
CT value is too high, a repeat specimen using a more sensitive
sampling technique such as a nasopharyngeal aspirate could be
requested. As this assay can only confidently detect 30:70
mutant:wildtype mixtures, if a patient continues to shed virus
despite appropriate treatment, performing the assay on sequential
specimens should be considered to detect an increase in the
mutant population to above this threshold. Finally, although this
assay is specific for influenza A/H1N1 2009 alternative primer sets
could be easily designed for seasonal H1N1 and H3N2 viruses.
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Results S1 Results for each sample with values for high-
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cells indicate that an assay has not been performed.
(XLS)
Author Contributions
Conceived and designed the experiments: ST PG IB. Performed the
experiments: ST FD AH YD. Analyzed the data: ST FD. Contributed
reagents/materials/analysis tools: ST FD KF PF. Wrote the paper: ST.
Revised the manuscript: FD AH YD PF IB PG.
References
1. Centers for Disease Control and Prevention (2009) Oseltamivir-resistant 2009
pandemic influenza A (H1N1) virus infection in two summer campers receiving
prophylaxis–North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58:
969–972.
2. Centers for Disease Control and Prevention (2009) Oseltamivir-resistant novel
influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle,
Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893–896.
3. Speers DJ, Williams SH, Pinder M, Moody HR, Hurt AC, et al. (2010)
Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient:
the first Australian case. Med J Aust 192: 166–168.
4. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, et al. (2009) Emergence
of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med
361: 2296–2297.
5. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, et al. (2010) A
community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza.
N Engl J Med 362: 86–87.
6. (2009) Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October
2009. Wkly Epidemiol Rec 84: 453–468.
7. Deyde VM, Gubareva LV (2009) Influenza genome analysis using pyrose-
quencing method: current applications for a moving target. Expert Rev Mol
Diagn 9: 493–509.
8. Varillas D, Bermejo-Martin JF, Almansa R, Rojo S, Nogueira B, et al. (2011) A
new method for detection of pandemic influenza virus using High Resolution
Melting analysis of the neuraminidase gene. J Virol Methods 171: 284–286.
9. Hurt AC, Barr IG, Hartel G, Hampson AW (2004) Susceptibility of human
influenza viruses from Australasia and South East Asia to the neuraminidase
inhibitors zanamivir and oseltamivir. Antiviral Res 62: 37–45.
10. Whiley DM, Bialasiewicz S, Bletchly C, Faux CE, Harrower B, et al. (2009)
Detection of novel influenza A(H1N1) virus by real-time RT-PCR. J Clin Virol
45: 203–204.
11. Guo L, Garten RJ, Foust AS, Sessions WM, Okomo-Adhiambo M, et al. (2009)
Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with
H274Y mutation by RT-PCR/restriction fragment length polymorphism assay.
Antiviral Res 82: 29–33.
12. Bolotin S, Robertson AV, Eshaghi A, De Lima C, Lombos E, et al. (2009)
Development of a novel real-time reverse-transcriptase PCR method for the
detection of H275Y positive influenza A H1N1 isolates. J Virol Methods 158:
190–194.
13. van der Vries E, Jonges M, Herfst S, Maaskant J, Van der Linden A, et al. (2010)
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A
(H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y)
substitution in neuraminidase. J Clin Virol 47: 34–37.
14. Carr MJ, Sayre N, Duffy M, Connell J, Hall WW (2008) Rapid molecular
detection of the H275Y oseltamivir resistance gene mutation in circulating
influenza A (H1N1) viruses. J Virol Methods 153: 257–262.
15. Chidlow GR, Harnett GB, Williams SH, Tempone SS, Speers DJ, et al. (2010)
The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses
using a real-time RT-PCR assay. J Virol Methods 169: 47–51.
16. Hindiyeh M, Ram D, Mandelboim M, Meningher T, Hirsh S, et al. (2010)
Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase
resistance mutation H275Y by real-time reverse transcriptase PCR. J Clin
Microbiol 48: 1884–1887.
17. Renaud C, Kuypers J, Corey L (2010) Diagnostic accuracy of an allele-specific
reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant
mutation in 2009 pandemic influenza A/H1N1 virus. J Clin Virol 49: 21–25.
18. Suzuki Y, Saito R, Sato I, Zaraket H, Nishikawa M, et al. (2011) Identification of
oseltamivir resistance among pandemic and seasonal influenza A(H1N1) viruses
by His275Tyr genotyping assay using cycling probe method. J Clin Microbiol
49: 125–130.
19. Medina RA, Rojas M, Tuin A, Huff S, Ferres M, et al. (2011) Development and
characterization of a highly specific and sensitive SYBR Green RT-PCR assay
for detection of the 2009 pandemic H1N1 influenza virus based on sequence
signatures. J Clin Microbiol 49: 355–344.
20. Steain MC, Dwyer DE, Hurt AC, Kol C, Saksena NK, et al. (2009) Detection of
influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir
using rolling circle amplification. Antiviral Res 84.
21. Hata M, Tanaka S, Yasui Y, Fujiwara N, Kobayashi S, et al. (2010) Rapid
genotypic assay for detection of oseltamivir-resistant influenza A (H1N1) viruses.
J Clin Microbiol 48: 1983–1984.
22. Mehta T, McGrath E, Bheemreddy S, Salimnia H, Abdel-Haq N, et al. (2010)
Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza
virus infection in immunocompromised patients: utility of cycle threshold values
of qualitative real-time reverse transcriptase PCR. J Clin Microbiol 48:
4326–4328.
HRM Detection of H275Y in Influenza A/H1N1 2009
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21446